Date  Sort Arrow Headline
Apr 29, 2019 Innovate Biopharmaceuticals Announces $8.7 Million Registered Direct Offering Priced At-the-Market
Apr 26, 2019 Innovate Biopharmaceuticals First Quarter 2019 Financial Results and Operational Progress Updates - Webcast Details
Apr 11, 2019 Innovate Biopharmaceuticals Presents Oral Poster at European Association for the Study of the Liver (EASL) Demonstrating Positive Effect of Larazotide on Reduced Intestinal Permeability in a NASH Preclinical Study
Apr 2, 2019 Innovate Biopharmaceuticals to Announce First Quarter 2019 Financial Results and to Provide Operational Progress Updates on April 29, 2019
Mar 26, 2019 Innovate Biopharmaceuticals Announces Collaboration with Institut Gustave Roussy to Study Regulation of Intestinal Permeability and the Gut Microbiota using Larazotide in Immuno-oncology Checkpoint Inhibitor Failure Pre-Clinical Models
Mar 19, 2019 Innovate Biopharmaceuticals Reports Financing to Initiate the First Phase 3 Clinical Trial in Celiac Disease, Fiscal Year 2018 Earnings and Key Corporate Highlights
Mar 18, 2019 Innovate Biopharmaceuticals to Discuss Fourth Quarter and Full Year 2018 Financial Results and to Provide Corporate and Operational Progress Updates on March 19, 2019
Mar 18, 2019 Innovate Biopharmaceuticals Announces Entry Into Securities Purchase Agreement to Fund Initiation of the First Phase 3 Celiac Disease Clinical Trial
Mar 13, 2019 Innovate Biopharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and to Provide Corporate and Operational Progress Updates on March 18, 2019
Mar 6, 2019 Innovate Biopharmaceuticals Announces Presentation at Cowen’s 39th Annual Health Care Conference in Boston